Vertaling van "pfizer clinical research " (Nederlands → Frans) :

Pfizer Clinical Research Unit gelegen te Brussel zoekt hemofiliepatiënten in het kader van een studie naar een nieuwe therapie
Notre Unité de Recherche Clinique Pfizer située à Bruxelles recherche des patients hémophiles pour l'étude d’une nouvelle thérapie

Pfizer Clinical Research Unit gelegen te Brussel zoekt mannen en vrouwen tussen de 45 en 75 jaar die in de voorbije drie jaren getroffen werden door een hartinfarct.
Notre Unité de Recherche Clinique Pfizer située à Bruxelles recherche des hommes et des femmes, âgés de 45 à 75 ans ayant eu un infarctus du myocarde au cours des trois dernières années.

Pfizer Clinical Research Unit opent deuren voor ‘Dag van de Zorg’
Pfizer Clinical Research Unit ouvre ses portes pour le ‘Dag van de Zorg’

De Pfizer Clinical Research Unit Brussels viert 20 jaar ervaring in klinisch fase 1 onderzoek
La Pfizer Clinical Research Unit Brussels célèbre ses 20 ans d'expérience dans les études cliniques de Phase 1

Onze Fase I-eenheid van Pfizer, die ook bekend staat als de Pfizer Clinical Research Unit (PCRU) bevindt zich op de twee bovenste verdiepingen van het Erasmus dagziekenhuis.
Dans le monde, Pfizer compte 3 Unités de Phase I, une à Singapour, une aux Etats-Unis à New Haven, et la troisième en Belgique à Anderlecht sur le site de l'hôpital Erasme, sur le campus universitaire du même nom. Notre Unité de Phase I de Pfizer, également appelée Pfizer Clinical Research Unit (PCRU), se trouve aux deux derniers étages de l’hôpital de jour de l’hôpital Erasme.

This release contains forward-looking information about an agreement by Pfizer to acquire FoldRx, and about FoldRx’s product candidate tafamidis, its other clinical and preclinical development programs and its technology platform, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and in its reports on Form 10-Q and Form 8-K.
Such risks and uncertainties include, among other things, the satisfaction of conditions to closing the agreement; the uncertainties inherent in research and development; whether and when a new drug application for tafamidis will be filed with the FDA; decisions by regulatory authorities regarding whether and when to approve any drug applications that have been or may be filed for tafamidis and that may be filed for any other product candidates that may be generated by FoldRx’s technology platform as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of tafamidis and such other product candidates; and competitive developments.

Pfizer Brussels Clinical Research Unit Route de Lennik 808 - 1070 Anderlecht Tel.: + 32 (0)2 556 70 11
Pfizer Brussels Clinical Research Unit Route de Lennik 808 - 1070 Anderlecht Tél.: + 32 (0)2 556 70 11